DE60213578D1 - Replikationsprozess des hepatitis c virus - Google Patents

Replikationsprozess des hepatitis c virus

Info

Publication number
DE60213578D1
DE60213578D1 DE60213578T DE60213578T DE60213578D1 DE 60213578 D1 DE60213578 D1 DE 60213578D1 DE 60213578 T DE60213578 T DE 60213578T DE 60213578 T DE60213578 T DE 60213578T DE 60213578 D1 DE60213578 D1 DE 60213578D1
Authority
DE
Germany
Prior art keywords
hcv
cells
nucleic acid
structural proteins
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213578T
Other languages
English (en)
Other versions
DE60213578T2 (de
Inventor
Czeslaw Wychowski
Gilles Duverlie
Jean Dubuisson
Andre Pillez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of DE60213578D1 publication Critical patent/DE60213578D1/de
Application granted granted Critical
Publication of DE60213578T2 publication Critical patent/DE60213578T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE60213578T 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus Expired - Lifetime DE60213578T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0105732 2001-04-27
FR0105732A FR2824072B1 (fr) 2001-04-27 2001-04-27 Procede de replication et de production du virus de l'hepatite c
PCT/FR2002/001422 WO2002088338A2 (fr) 2001-04-27 2002-04-25 Procede de replication du virus de l'hepatite c

Publications (2)

Publication Number Publication Date
DE60213578D1 true DE60213578D1 (de) 2006-09-14
DE60213578T2 DE60213578T2 (de) 2007-08-09

Family

ID=8862798

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213578T Expired - Lifetime DE60213578T2 (de) 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus

Country Status (12)

Country Link
US (3) US7314710B2 (de)
EP (1) EP1381675B1 (de)
JP (1) JP2004527252A (de)
AT (1) ATE335073T1 (de)
AU (1) AU2002257890B2 (de)
CA (1) CA2445596A1 (de)
DE (1) DE60213578T2 (de)
ES (1) ES2269684T3 (de)
FR (1) FR2824072B1 (de)
MX (1) MXPA03009736A (de)
NZ (1) NZ529037A (de)
WO (1) WO2002088338A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
EP1801116A1 (de) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV-Replikon-Shuttlevektoren
AU2008262333B2 (en) * 2007-06-08 2014-07-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US10590391B2 (en) 2007-06-08 2020-03-17 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
GB0718446D0 (en) * 2007-09-21 2007-10-31 Prendergast Patrick T Compositions and methods for the treatment of infection
WO2010057015A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
WO1994025064A1 (en) * 1993-05-04 1994-11-10 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMANSERVIC ES Hepatitis c virus cell propagation and related methods
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
AU1822195A (en) * 1995-02-10 1996-08-27 Consiglio Nazionale Delle Ricerche Process to "in vitro" propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c

Also Published As

Publication number Publication date
NZ529037A (en) 2006-05-26
WO2002088338A3 (fr) 2003-04-03
ATE335073T1 (de) 2006-08-15
US20040142320A1 (en) 2004-07-22
AU2002257890B2 (en) 2008-05-22
FR2824072A1 (fr) 2002-10-31
WO2002088338A2 (fr) 2002-11-07
CA2445596A1 (fr) 2002-11-07
MXPA03009736A (es) 2005-03-07
US20100159467A1 (en) 2010-06-24
US7314710B2 (en) 2008-01-01
US7655406B2 (en) 2010-02-02
EP1381675A2 (de) 2004-01-21
ES2269684T3 (es) 2007-04-01
FR2824072B1 (fr) 2004-03-12
US20080220410A1 (en) 2008-09-11
EP1381675B1 (de) 2006-08-02
JP2004527252A (ja) 2004-09-09
DE60213578T2 (de) 2007-08-09

Similar Documents

Publication Publication Date Title
Luo et al. Role of the 5′-proximal stem-loop structure of the 5′ untranslated region in replication and translation of hepatitis C virus RNA
Funk et al. RNA structures required for production of subgenomic flavivirus RNA
Wilson et al. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region
Alt et al. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides
Gamarnik et al. Interactions of viral protein 3CD and poly (rC) binding protein with the 5′ untranslated region of the poliovirus genome
Shimakami et al. Base pairing between hepatitis C virus RNA and microRNA 122 3′ of its seed sequence is essential for genome stabilization and production of infectious virus
Bailey et al. Structure of the 5′ nontranslated region of the coxsackievirus b3 genome: chemical modification and comparative sequence analysis
Beard et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus
Sun et al. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
Tuplin et al. Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus
Behrens et al. Characterization of an autonomous subgenomic pestivirus RNA replicon
Davis et al. Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses
Song et al. Dengue and Zika virus 5′ untranslated regions harbor internal ribosomal entry site functions
Jackson et al. Internal initiation of translation of picornavirus RNAs
Gallei et al. RNA recombination in vivo in the absence of viral replication
Laporte et al. Comparative analysis of translation efficiencies of hepatitis C virus 5′ untranslated regions among intraindividual quasispecies present in chronic infection: opposite behaviors depending on cell type
Khromykh et al. Significance in replication of the terminal nucleotides of the flavivirus genome
Murray et al. Persistent replication of hepatitis C virus replicons expressing the β-lactamase reporter in subpopulations of highly permissive Huh7 cells
Zhao et al. Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus
Friebe et al. Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly
DE60333042D1 (de) Eine aus dem genom von hepatitis-c-virus (hcv) genotyp 2a stammende nukleinsäure enthaltendes nukleinsäurekonstrukt und zelle mit dem dahinein transferierten nukleinsäurekonstrukt
Washenberger et al. Hepatitis C virus RNA: dinucleotide frequencies and cleavage by RNase L
WO2006038129A3 (en) Hepatitis c virus replication system
ATE335073T1 (de) Replikationsprozess des hepatitis c virus
Atieh et al. New reverse genetics and transfection methods to rescue arboviruses in mosquito cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition